Lesley Tilson

Summary

Affiliation: St James's Hospital
Country: Ireland

Publications

  1. doi request reprint Pharmacoeconomic evaluation in Ireland: a review of the process
    Lesley Tilson
    National Centre for Pharmacoeconomics, St James s Hospital, James s Street, Dublin 8, Ireland
    Pharmacoeconomics 28:307-22. 2010
  2. pmc Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland
    Linda Sharp
    National Cancer Registry Ireland, Cork Airport Business Park, Kinsale Road, Cork, Ireland
    BMC Health Serv Res 13:105. 2013
  3. pmc Proton pump inhibitors: potential cost reductions by applying prescribing guidelines
    Caitriona Cahir
    HRB Centre for Primary Care Research, Division of Population Health Science, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland
    BMC Health Serv Res 12:408. 2012
  4. doi request reprint Cost of care for colorectal cancer in Ireland: a health care payer perspective
    L Tilson
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
    Eur J Health Econ 13:511-24. 2012
  5. doi request reprint Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland
    L Tilson
    National Centre for Pharmacoeconomics, St James Hospital, Dublin 8, Ireland
    Vaccine 29:7463-73. 2011
  6. ncbi request reprint Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation
    Lesley Tilson
    National Centre for Pharmacoeconomics, St James s University Teaching Hospital, James s St, Dublin 8, Ireland
    Eur J Public Health 18:275-82. 2008
  7. doi request reprint Public drug expenditure in the Republic of Ireland
    Michael Barry
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
    Expert Rev Pharmacoecon Outcomes Res 10:239-45. 2010
  8. doi request reprint Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database
    Cara Usher
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
    Clin Ther 34:632-9. 2012
  9. ncbi request reprint Pricing and reimbursement of drugs in Ireland
    Michael Barry
    National Centre for Pharmacoeconomics, St James s Hospital, 8 Dublin, Ireland
    Eur J Health Econ 5:190-4. 2004
  10. doi request reprint A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting
    Laura McCullagh
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
    Pharmacoeconomics 27:829-46. 2009

Collaborators

Detail Information

Publications17

  1. doi request reprint Pharmacoeconomic evaluation in Ireland: a review of the process
    Lesley Tilson
    National Centre for Pharmacoeconomics, St James s Hospital, James s Street, Dublin 8, Ireland
    Pharmacoeconomics 28:307-22. 2010
    ..NCPE recommendations broadly concurred with those of UK agencies for the majority of appraisals...
  2. pmc Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland
    Linda Sharp
    National Cancer Registry Ireland, Cork Airport Business Park, Kinsale Road, Cork, Ireland
    BMC Health Serv Res 13:105. 2013
    ..As an illustration of such an approach, we estimated annual health service resource requirements and health outcomes over the first decade of a population-based colorectal cancer screening programme in Ireland...
  3. pmc Proton pump inhibitors: potential cost reductions by applying prescribing guidelines
    Caitriona Cahir
    HRB Centre for Primary Care Research, Division of Population Health Science, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland
    BMC Health Serv Res 12:408. 2012
    ..This study aims to establish potential cost savings in a community drug scheme for a one year period according to published clinical and cost-effective guidelines for PPI prescribing...
  4. doi request reprint Cost of care for colorectal cancer in Ireland: a health care payer perspective
    L Tilson
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
    Eur J Health Econ 13:511-24. 2012
    ..Management options for colorectal cancer have expanded in recent years. We estimated average lifetime cost of care for colorectal cancer in Ireland in 2008, from the health care payer perspective...
  5. doi request reprint Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland
    L Tilson
    National Centre for Pharmacoeconomics, St James Hospital, Dublin 8, Ireland
    Vaccine 29:7463-73. 2011
    ..Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective...
  6. ncbi request reprint Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation
    Lesley Tilson
    National Centre for Pharmacoeconomics, St James s University Teaching Hospital, James s St, Dublin 8, Ireland
    Eur J Public Health 18:275-82. 2008
    ....
  7. doi request reprint Public drug expenditure in the Republic of Ireland
    Michael Barry
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
    Expert Rev Pharmacoecon Outcomes Res 10:239-45. 2010
    ..Since September 2009, all new pharmaceutical products are considered for pharmacoeconomic assessment. Generic substitution and reference pricing are to be introduced in 2011...
  8. doi request reprint Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database
    Cara Usher
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
    Clin Ther 34:632-9. 2012
    ..In the current national and international economic climate, it is anticipated that demand on these services will continue to grow...
  9. ncbi request reprint Pricing and reimbursement of drugs in Ireland
    Michael Barry
    National Centre for Pharmacoeconomics, St James s Hospital, 8 Dublin, Ireland
    Eur J Health Econ 5:190-4. 2004
    ..Prior to reimbursement under the community drugs schemes, a medicine must be included in the GMS code book or positive list. A demonstration of cost-effectiveness is not a pre-requisite for reimbursement...
  10. doi request reprint A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting
    Laura McCullagh
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
    Pharmacoeconomics 27:829-46. 2009
    ..Rivaroxaban (Xarelto) is a direct factor Xa inhibitor and dabigatran etexilate (Pradaxa) is a prodrug of the active compound dabigatran, which inhibits thrombin...
  11. doi request reprint Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland
    Lesley Tilson
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
    Value Health 11:898-903. 2008
    ..To evaluate the cost-effectiveness of implementing a universal infant 7-valent pneumococcal conjugate vaccine (PCV7) vaccination program in the Irish health-care setting from the health-care payers' perspective...
  12. ncbi request reprint The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland
    Lesley Tilson
    National Centre for Pharmacoeconomics, Ireland
    Eur J Health Econ 6:267-73. 2005
    ..0 million on the GMS and <euro>6.4 million on the DP scheme. Comparison of these results with a similar analysis of 2001 data illustrates the potential for an increase in savings over time...
  13. doi request reprint Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model
    Cara Usher
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
    Vaccine 26:5654-61. 2008
    ..This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer...
  14. ncbi request reprint The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Lesley Tilson
    National Centre for Pharmacoeconomics, Dublin, Ireland
    Eur J Health Econ 5:341-4. 2004
    ..The estimated savings were statistically significant for the Danish and average European price but not for the UK price. This study demonstrates the high ex-wholesale price of prescription medications in Ireland...
  15. doi request reprint Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010
    Kathleen Bennett
    Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James s Hospital, Dublin, Ireland
    Value Health 12:10-5. 2009
    ..Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland...
  16. doi request reprint Health Technology Assessment International 7th Annual Meeting: Dublin, Ireland, 6–9 June 2010
    Emer Fogarty
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
    Expert Rev Pharmacoecon Outcomes Res 10:501-3. 2010
    ..There was also a lively social program with the conference dinner held at the Guinness Storehouse...
  17. ncbi request reprint Recent developments in pricing and reimbursement of medicines in Ireland
    Michael Barry
    National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
    Expert Rev Pharmacoecon Outcomes Res 7:605-11. 2007
    ..The new Health Information and Quality Authority (HIQA) was established under the Health Act 2007 and will lead the development of Health Technology Assessment (HTA) across the health service...